ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy
Laura Soumoy(University of Mons), Fabrice Journé(Université Libre de Bruxelles)
Cited by 0
Related Papers
Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells
|British Journal of Cancer|2004|22
Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells
|Breast Cancer Research|2008|15
ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy
|Cancer Cell International|2024|9
Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit
|Molecular Cancer Research|2021|8
Therapeutic Potential of Glutaminase Inhibition Targeting Metabolic Adaptations in Resistant Melanomas to Targeted Therapy
|International Journal of Molecular Sciences|2025|5